ONC201/TIC10 enhances durability of mTOR inhibitor everolimus in metastatic ER+ breast cancer

The mTOR inhibitor, everolimus, is an important clinical management component of metastatic ER+ breast cancer (BC). However, most patients develop resistance and progress on therapy, highlighting the need to discover strategies that increase mTOR inhibitor effectiveness. We developed ER+ BC cell lin...

Descripción completa

Detalles Bibliográficos
Autores principales: Farmaki, Elena, Nath, Aritro, Emond, Rena, Karimi, Kimya L, Grolmusz, Vince K, Cosgrove, Patrick A, Bild, Andrea H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: eLife Sciences Publications, Ltd 2023
Materias:
Cancer Biology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10541180/
https://www.ncbi.nlm.nih.gov/pubmed/37772709
http://dx.doi.org/10.7554/eLife.85898

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10541180/
https://www.ncbi.nlm.nih.gov/pubmed/37772709
http://dx.doi.org/10.7554/eLife.85898

Ejemplares similares